tetrazanbigen: a synthetic azagonane with significant antitumor effects on common solid tumors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124203923 |
| CHEMBL ID | 4781829 |
| MeSH ID | M0550880 |
| Synonym |
|---|
| tetrazanbigen, >=98% (hplc) |
| tnbg |
| CHEMBL4781829 |
| tetrazanbigen |
| AKOS040754174 |
Tetrazanbigen (TNBG) is a newly synthesized compound with an isoquinoline moiety. Its antitumour effects were evaluated in in-vitro and in- vivo models.
| Excerpt | Reference |
|---|---|
| "Tetrazanbigen (TNBG) is a newly synthesized compound with an isoquinoline moiety, and its antitumour effects were evaluated in in-vitro and in-vivo models." | ( Antitumour effects of tetrazanbigen against human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in vivo. Chen, X; Lan, Z; Li, L; Li, W; Xia, Z; Yang, X; Yu, Y; Yuan, Y; Zhang, X; Zheng, X, 2015) |
| "Tetrazanbigen (TNBG) is a novel synthetic antitumor drug with significant antitumor effects on common solid tumors in vitro and in vivo. " | ( Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701. Gu, R; Huang, K; Li, L; Li, W; Liu, H; Yang, X; Yu, Y; Yuan, Y, 2009) |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1707994 | Inhibition of colony formation in human A549 cells at 3 uM incubated for 3 days followed by drug-free medium replacement for every 3 days for 12 days by crystal violet staining based assay | |||
| AID1707992 | Thermodynamic solubility in pH 7.4 phosphate buffer incubated for 6 hrs followed by further incubation for 18 hrs with shaking by UV-HPLC analysis | |||
| AID1707991 | Antiproliferative activity against human QSG7701 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay | |||
| AID1708062 | Induction of apoptosis in human A549 cells at 2 uM incubated for 48 hrs by FITC Annexin V/propidium iodide staining based flow cytometry | |||
| AID1707989 | Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay | |||
| AID1707990 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay | |||
| AID1707988 | Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||